CA3025063A1 - Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central - Google Patents

Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central

Info

Publication number
CA3025063A1
CA3025063A1 CA3025063A CA3025063A CA3025063A1 CA 3025063 A1 CA3025063 A1 CA 3025063A1 CA 3025063 A CA3025063 A CA 3025063A CA 3025063 A CA3025063 A CA 3025063A CA 3025063 A1 CA3025063 A1 CA 3025063A1
Authority
CA
Canada
Prior art keywords
seq
chondroitinase
composition
polypeptide
deletion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3025063A
Other languages
English (en)
Inventor
Elliott A. Gruskin
Anthony O. Caggiano
Gargi Roy
Rohini D'souza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Priority claimed from CA2525784A external-priority patent/CA2525784C/fr
Publication of CA3025063A1 publication Critical patent/CA3025063A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3025063A 2003-05-16 2004-05-17 Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central Abandoned CA3025063A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47123903P 2003-05-16 2003-05-16
US47124003P 2003-05-16 2003-05-16
US60/471,239 2003-05-16
US60/471,240 2003-05-16
US60/471,300 2003-05-16
US47437203P 2003-05-29 2003-05-29
US60/474,372 2003-05-29
CA2525784A CA2525784C (fr) 2003-05-16 2004-05-17 Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central
US47130005P 2005-05-16 2005-05-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2525784A Division CA2525784C (fr) 2003-05-16 2004-05-17 Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central

Publications (1)

Publication Number Publication Date
CA3025063A1 true CA3025063A1 (fr) 2004-12-23

Family

ID=64456681

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025063A Abandoned CA3025063A1 (fr) 2003-05-16 2004-05-17 Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central

Country Status (1)

Country Link
CA (1) CA3025063A1 (fr)

Similar Documents

Publication Publication Date Title
US9528102B2 (en) Proteoglycan degrading mutants for treatment of CNS
EP2354155A2 (fr) Protéines de fusion pour le traitement du SNC
AU2016204464B2 (en) Proteoglycan degrading mutants for treatment of cns
AU2013201097B2 (en) Proteoglycan degrading mutants for treatment of cns
CA3025063A1 (fr) Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central
AU2014265113A1 (en) Fusion proteins for the treatment of cns

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190521

FZDE Discontinued

Effective date: 20220311

FZDE Discontinued

Effective date: 20220311